
Alcon noted additional operational updates alongside the announcement.

Alcon noted additional operational updates alongside the announcement.

At 12 weeks posttreatment, all 4 of the patients showed improvement in the form of a lower logMAR.

The company is developing a one-time, non-AAV2 gene replacement therapy to restore, treat, and prevent blindness of patients with RPE65 mutation-associated retinopathies.